tiprankstipranks
Trending News
More News >
MaaT Pharma (FR:MAAT)
:MAAT
France Market
Advertisement

MaaT Pharma (MAAT) AI Stock Analysis

Compare
3 Followers

Top Page

FR:MAAT

MaaT Pharma

(MAAT)

Select Model
Select Model
Select Model
Neutral 44 (OpenAI - 4o)
Rating:44Neutral
Price Target:
€4.00
▼(-7.41% Downside)
MaaT Pharma's overall stock score is primarily impacted by its financial performance, which reflects significant challenges due to ongoing losses and high leverage. Technical analysis shows neutral indicators, while valuation is low due to negative earnings. The absence of earnings call data and corporate events means these factors do not influence the score.
Positive Factors
Revenue Growth
Strong revenue growth indicates increasing demand for MaaT Pharma's products, suggesting successful market penetration and potential for future expansion.
Product Pipeline
A robust product pipeline in microbiome-based therapies positions MaaT Pharma well for long-term growth in the healthcare sector, particularly in oncology and hematology.
Partnerships and Collaborations
Strategic partnerships and collaborations enhance MaaT Pharma's research capabilities and facilitate the commercialization of its therapies, supporting sustainable revenue streams.
Negative Factors
High Leverage
High leverage increases financial risk and limits flexibility, potentially impacting MaaT Pharma's ability to invest in R&D and growth initiatives.
Negative Cash Flow
Negative cash flow challenges the company's ability to sustain operations without external financing, posing a risk to long-term viability.
Profitability Challenges
Significant operating losses and negative margins highlight ongoing profitability challenges, which could hinder MaaT Pharma's ability to achieve financial stability.

MaaT Pharma (MAAT) vs. iShares MSCI France ETF (EWQ)

MaaT Pharma Business Overview & Revenue Model

Company DescriptionMaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.
How the Company Makes MoneyMaaT Pharma makes money primarily through the development and commercialization of its microbiome-based therapeutics. The company generates revenue from licensing agreements, research collaborations, and milestone payments with pharmaceutical companies and research institutions. Additionally, MaaT Pharma may earn income from grants and funding related to its research and development activities. Key partnerships with academic and commercial entities contribute to its earnings by facilitating the advancement and potential market introduction of its therapeutic products.

MaaT Pharma Financial Statement Overview

Summary
MaaT Pharma is experiencing financial challenges typical of biotechnology firms, with ongoing losses and high leverage. Despite revenue growth, the company faces high operating losses and negative cash flows. The balance sheet reflects high debt levels, and the cash flow statement indicates difficulties in generating positive cash flows.
Income Statement
45
Neutral
MaaT Pharma has shown revenue growth over the years, with a 44.36% increase from 2023 to 2024. However, the company is still operating at a loss, with a negative net profit margin of -898.45% in 2024. The gross profit margin in 2024 was 61.13%, indicating some efficiency in covering the cost of goods sold. EBIT and EBITDA margins remain negative, reflecting significant operating losses.
Balance Sheet
35
Negative
The company's balance sheet reveals a high debt-to-equity ratio of 1.54 in 2024, suggesting high leverage. The equity ratio decreased to 26.84%, indicating a decline in equity relative to total assets. Return on equity remains negative due to continued net losses, highlighting profitability challenges.
Cash Flow
40
Negative
Operating cash flow is negative and worsening, with a free cash flow of -22.79 million in 2024. The operating cash flow to net income ratio is 0.76, indicating cash flow issues in supporting net losses. The free cash flow to net income ratio is 0.79, suggesting limited free cash available relative to net losses.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue3.92M3.22M2.23M1.43M972.00K0.00
Gross Profit1.56M1.97M784.00K1.09M806.00K-164.00K
EBITDA-31.11M-26.34M-22.07M-13.10M-8.57M-6.58M
Net Income-31.13M-28.90M-19.72M-13.71M-9.02M-5.35M
Balance Sheet
Total Assets48.88M38.50M42.93M44.73M49.42M24.28M
Cash, Cash Equivalents and Short-Term Investments15.04M20.22M24.31M35.31M43.30M19.91M
Total Debt14.40M15.96M14.07M11.36M5.81M6.08M
Total Liabilities40.58M28.16M22.46M17.91M9.56M8.34M
Stockholders Equity8.29M10.34M20.47M26.81M39.86M15.94M
Cash Flow
Free Cash Flow-25.58M-22.79M-19.76M-13.27M-8.17M-6.13M
Operating Cash Flow-24.80M-22.04M-18.67M-12.61M-7.93M-5.81M
Investing Cash Flow-820.00K-416.00K-440.00K-815.00K-238.00K-523.00K
Financing Cash Flow9.51M18.33M8.14M5.36M31.56M20.84M

MaaT Pharma Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price4.32
Price Trends
50DMA
4.42
Negative
100DMA
4.74
Negative
200DMA
5.51
Negative
Market Momentum
MACD
-0.01
Negative
RSI
49.62
Neutral
STOCH
31.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:MAAT, the sentiment is Neutral. The current price of 4.32 is above the 20-day moving average (MA) of 4.32, below the 50-day MA of 4.42, and below the 200-day MA of 5.51, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 49.62 is Neutral, neither overbought nor oversold. The STOCH value of 31.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:MAAT.

MaaT Pharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
59
Neutral
€170.81M111.76%-22.45%
53
Neutral
€141.71M-30.84-62.40%-10.91%-25.57%
53
Neutral
€105.21M-40.00%10.87%
52
Neutral
€129.43M-52.76%-96.92%-175.84%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
$245.84M-48.02%327.14%49.02%
44
Neutral
€68.30M52.55%-5.97%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:MAAT
MaaT Pharma
4.32
-3.12
-41.94%
FR:TNG
Transgene
1.35
0.50
59.01%
FR:OSE
OSE Immunotherapeutics SA
6.19
-3.66
-37.16%
FR:ALCLS
Cellectis SA
2.99
1.25
71.44%
FR:ABNX
ABIONYX Pharma SA
4.09
2.86
231.44%
FR:ALSEN
Sensorion SAS
0.37
-0.38
-50.68%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 14, 2025